Increased Serum Hepcidin Levels in Subjects with the Metabolic Syndrome: A Population Study (original) (raw)

Open Access

Peer-reviewed

Research Article

Increased Serum Hepcidin Levels in Subjects with the Metabolic Syndrome: A Population Study

PLOS

x

Figures

Abstract

The recent discovery of hepcidin, the key iron regulatory hormone, has changed our view of iron metabolism, which in turn is long known to be linked with insulin resistant states, including type 2 diabetes mellitus and the Metabolic Syndrome (MetS). Serum ferritin levels are often elevated in MetS (Dysmetabolic hyperferritinemia - DHF), and are sometimes associated with a true mild-to-moderate hepatic iron overload (dysmetabolic iron overload syndrome - DIOS). However, the pathophysiological link between iron and MetS remains unclear. This study was aimed to investigate, for the first time, the relationship between MetS and hepcidin at population level. We measured serum hepcidin levels by Mass Spectrometry in 1,391 subjects from the Val Borbera population, and evaluated their relationship with classical MetS features. Hepcidin levels increased significantly and linearly with increasing number of MetS features, paralleling the trend of serum ferritin. In multivariate models adjusted for relevant variables including age, C-Reactive Protein, and the HFE C282Y mutation, ferritin was the only significant independent predictor of hepcidin in males, while in females MetS was also independently associated with hepcidin. Overall, these data indicate that the fundamental iron regulatory feedback is preserved in MetS, i.e. that hepcidin tends to progressively increase in response to the increase of iron stores. Due to recently discovered pleiotropic effects of hepcidin, this may worsen insulin resistance and contribute to the cardiovascular complications of MetS.

Citation: Martinelli N, Traglia M, Campostrini N, Biino G, Corbella M, Sala C, et al. (2012) Increased Serum Hepcidin Levels in Subjects with the Metabolic Syndrome: A Population Study. PLoS ONE 7(10): e48250. https://doi.org/10.1371/journal.pone.0048250

Editor: Giorgio Sesti, Universita Magna-Graecia di Catanzaro, Italy

Received: July 27, 2012; Accepted: September 21, 2012; Published: October 29, 2012

Copyright: © 2012 Martinelli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by the Italian Ministry of University and Research (grant no. 200989KXFN) and by Fondazione Cariverona, project Verona Nanomedicine Initiative to DG and Telethon Fondazione onlus (grant no. GGP08089) and Regione Lombardia Sal-11, ID 17389 to CC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

The “metabolic syndrome” (MetS) is a condition highly prevalent in western countries, involving near one fourth of the adult population [1]. Although definitions vary, the essential features of MetS are represented by the deadly quartet of hyperglycemia, dyslipidemia, hypertension, and obesity [2], leading to a substantial cardiovascular risk, but also to risk of hepatic diseases, namely nonalcoholic fatty liver disease (NAFLD). In 1997, Moirand et al. first reported the presence of histologically proven liver iron overload in overweight subjects with abnormal glucose metabolism and dyslipidemia [3]. This condition, later designated as dysmetabolic iron overload syndrome (DIOS) [4], is now known to occur in about one third of subjects with NAFLD and represents the most severe counterpart of the so-called dysmetabolic hyperferritinemia (DHF) (for a recent extensive review, see Dongiovanni et al [5]). The latter in turn is by far the commonest cause of consultation for increased serum ferritin levels in clinical practice [6]. Nevertheless, the complex pathophysiological links between iron and metabolic derangements remain poorly understood [5]. In the last ten years, hepcidin has emerged as the key iron-regulatory hormone [7]. This defensin-like 25 amino acid peptide is mainly produced by the liver in response to increased plasma or tissue iron to homeostatically down-regulate absorption and recycling of the metal [8]. At the molecular level, hepcidin acts by binding and inactivating its cell membrane receptor ferroportin, the only known cellular iron exporter [9]. Ferroportin is particularly expressed by cells critical for iron homeostasis, like absorbing duodenal enterocytes, reticuloendothelial macrophages (involved in iron storage and recycling), and hepatocytes (involved in iron storage and endocrine regulation) [9]. Hepcidin is also upregulated by inflammatory cytokines, a response believed to contribute to host defense by subtracting iron from invading pathogens [10]. Given its central role in iron homeostasis, hepcidin represents an appealing candidate to be investigated in subjects with MetS features, but until now methodological difficulties [11] have hampered large epidemiological studies. Taking advantage from the recently completed iron section of the Val Borbera Study (VBS) [12], this study was aimed to investigate the relationships between hepcidin and the main features of MetS at population level.

Materials and Methods

Details on the VBS population have been previously reported elsewhere [12]. Individuals aged 18 years or older were eligible to participate in the study. In this analysis we included subjects with available complete data allowing their classification according to established criteria for MetS [2]. In detail, the following features were considered: 1) abdominal obesity, defined as the presence of waist circumference ≥94 cm in men or ≥80 cm in women; 2) fasting plasma glucose ≥100 mg/dL or drug treatment for elevated blood glucose; 3) serum triglycerides ≥150 mg/dL or drug treatment for elevated triglycerides; 4) serum HDL cholesterol (HDL-C) <40 mg/dL in men and <50 mg/dL in women or drug treatment for low HDL-C; 5) blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure. Subjects were considered to have MetS when they had at least three of the above-mentioned five traits. Homozygotes for the hemochromatosis mutation (C282Y on the HFE gene) were excluded (n = 7). A total of 1,391 subjects, 616 men and 775 women were finally included in the present study. Fasting blood samples obtained early in the morning were analyzed the same day or stored at −80°C for further analysis. Routine blood parameters and serum hepcidin were determined by standard methods and by mass spectrometry, respectively, as previously described [12]. The study was approved by the ethical committees of San Raffaele Hospital Milano, Regione Piemonte, and Azienda Integrata Ospedaliera Universitaria of Verona, Italy. All subjects gave written informed consent.

Statistical Analyses

All calculations were performed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). As many of the continuous variables of interest, including serum hepcidin and ferritin, showed a non-Gaussian distribution, their values were log-transformed and expressed as geometric means with 95% confidence intervals (CIs).

Since some subjects had serum hepcidin levels below the lower limit of detection (LLOD) for our method (0.55 nM), to allow a correct analysis these subjects were considered as having hepcidin “0”, and hepcidin was log-transformed after the addition of 0.1 to each value in the dataset. Quantitative data were analyzed using the Student’s t test or by analysis of variance (ANOVA) with polynomial contrasts for linear trend, when appropriate. Qualitative data were analyzed with the χ2 test and with χ2 analysis for linear trend, when appropriate. Correlations between quantitative variables were assessed using Pearson’s coefficient. Most of the hepcidin-related analyses were done separately in males and females, since we [12] and others [13] recently reported substantial gender differences in hepcidin serum levels. Particularly, women during the fertile period showed hepcidin levels significantly lower (i.e. less than half) than men of the same age range. Similarly, since MetS subjects were older than those without MetS, analyses were always adjusted for age. Independent determinants of serum hepcidin levels were assessed through a series of linear regression models, using either MetS by itself or individual MetS features as covariates, and adjusting for age, ferritin, C-Reactive Protein (CRP) and C282Y HFE mutation. Two-sided p values <0.05 were considered statistically significant.

Results

Table 1 summarizes the main clinical, anthropometrical and biochemical features of the population studied, including stratification by gender. Using these data, we calculated the population prevalence of MetS features (shown in Table S1). Overall, 304 individuals (21.9%) could be classified as having MetS using the criteria defined above. Table 2 shows the biochemical iron parameters of the VB subjects stratified for having or not the MetS. Of note, MetS subjects had significantly higher serum levels of both ferritin and hepcidin as compared to subjects without MetS (geometric means for ferritin: 102 versus 61 µg/L, P<0.001; for hepcidin: 7.95 versus 4.29 nM, P<0.001). Such results remained statistically significant also after adjusting for age and sex (Table 2, last column). Beyond mean values, to evaluate the proportion of MetS individuals with high hepcidin values, we stratified hepcidin levels into quartiles considering subjects with no or just one MetS feature as the reference group. Of note, subjects with undetectable hepcidin levels were significantly underrepresented in the MetS group as compared to the non-MetS group (Table 2). As shown in Figure S1, near 50% of subjects with ≥4 MetS features had hepcidin values in the top quartile of the reference group. We then evaluated the behavior of these two parameters according to the number of MetS features (0 to 5, where the last two categories were merged because of the small number of subjects with all five the features). According to our previous data in a different population [14], serum ferritin levels increased linearly according to increasing number of MetS features, both in males and in females (Figures S2 A–C). The same behavior was observed for serum hepcidin levels, again both in males and in females (Figures 1 A–C). At univariate analyses (Table S2), the variable showing the strongest association with hepcidin was ferritin (beta coefficients = 0.559, and 0.585 in males and females, respectively; P<0.001 for both). Of note, beta coefficients and slopes were quite similar when correlations were made separately in subjects with or without the MetS (Figure S3), suggesting that the homeostatic loop of hepcidin in response to iron stores is well preserved in MetS.

We then performed a series of multiple logistic models to assess the influence of MetS or its individual components on hepcidin levels in both sexes after adjustment for age and all the other relevant covariates, i.e. ferritin, CRP, and C282Y HFE mutation (whose allelic frequency in the VB population was 0.065) [12]. When considering MetS as a comprehensive covariate (Table 3) in a model adjusted for age and serum ferritin, it was independently associated with hepcidin in females but not in males, although the standardized beta coefficient (0.093) for MetS was quite lower than that for ferritin (standardized beta coefficient = 0.580). This association remained statistically significant also after adjustment for CRP and C282Y HFE mutation (standardized beta coefficient = 0.080; P = 0.012), as well as after including in the model hemoglobin, uric acid, and creatinine (standardized beta coefficient = 0.073; P = 0.028). Considering the individual MetS features as covariates (Table S3), the only independent association was observed for abnormal glucose metabolism in females, again with a beta coefficient (0.080) much lower than that of ferritin (0.638). Since the interaction term between ferritin and MetS was significant in females (P<0.001), hepcidin levels were stratified in this group according to both ferritin levels and presence/absence of MetS. As shown in Figure S4, the MetS-associated increase of hepcidin was particularly evident (and statistically significant) in females with the lower ferritin values. A similar trend was not observed in males (data not shown). Finally, when females were stratified on the basis of hepcidin levels, the prevalence of MetS increased progressively from the lowest to the highest strata (Figure S5A). This association remained statistically significant after adjustment for age and ferritin (Figure S5B).

Discussion

In the recent years, a bulk of evidence, particularly from epidemiological studies [14]–[17] have established a link between iron metabolism and insulin resistant states, including type 2 diabetes mellitus and the MetS (for recent reviews, see Dongiovanni et al [5] and Rajpathak et al [18]). Accordingly, experimental studies [19], recently confirmed by a sophisticated approach in C. Elegans [20], have revealed a complex interplay between insulin/IGF-1 signaling and ferritin expression. On the other hand, some prospective studies [16], [17] have shown a positive association between baseline levels of ferritin, i.e. the best available serum marker of body iron stores [21], and development of type 2 diabetes. On this basis, it has been postulated that iron may promote insulin resistance through its well-known pro-oxidant properties [22]. Although this causal link remains debated, it is undisputed that dysmetabolic subjects often have high serum ferritin levels, being the so-called dysmetabolic hyperferritinemia (DHF) the commonest cause of mild to moderate hyperferritinemia in clinical practice [6]. The histopathological entity known as dysmetabolic iron overload syndrome (DIOS, formerly designated as “insulin resistance-associated hepatic iron overload – IRHIO) [4] is now believed to represent the most severe clinical expression of DHF [5], where variable degrees of stainable iron coexist with classical features of NAFLD, and serum ferritin levels predicts advanced hepatic fibrosis [23].

Our view of iron overload disorders has radically changed by the discovery of hepcidin [7], which has been demonstrated to be inappropriately low in genetic hemochromatosis [8]. On the other hand, pilot studies have found high hepcidin levels in either serum [24] or urine [25] of few DIOS subjects (n = 16 to 24), suggesting a distinct pathogenesis. Supporting and extending these observations, our results establish for the first time at population level that subjects with MetS have increased serum levels of hepcidin. In subjects of both sexes hepcidin increased linearly with increasing number of the five classical MetS features, paralleling the previously described behavior of serum ferritin [14]. Of note, serum ferritin was the strongest predictor of hepcidin, while in our analyses CRP, the classical systemic marker of inflammation, was not a significant determinant of both parameters. Taken together, these data indicate that the fundamental iron regulatory feedback is preserved in MetS, i.e. that hepcidin tends to progressively increase in response to a moderate increase of iron stores, likely in the attempt to counterbalance it by limiting intestinal iron absorption. As a corollary, once simple and cheap hepcidin assays will be available in the future, the hepcidin:ferritin ratio may be proven helpful in practice for rapid distinction of DHF/DIOS from other iron overload disorders where hepcidin is inappropriately low, as mentioned above.

While our data definitively exclude hepcidin deficiency as the underlying mechanism, the key-point that remains to be addressed is the primum movens leading to an increase of iron stores in some dysmetabolic subjects. Aigner et al. proposed that some cytokines produced by the expanding adipose tissue (i.e. TNF-α and other “adipokines”) may down-regulate hepatic ferroportin leading to intracellular iron accumulation and compensatory stimulation of hepcidin [26]. Things are further complicated by the fact that the adipose tissue by itself may be a source of hepcidin [27]. On the other hand, some findings in women may be in agreement with these hypotheses. Indeed, we found that in women MetS was independently associated to hepcidin in multivariate models. Of note, when women with or without MetS were stratified by ferritin levels, MetS women with ferritin in the lower range had hepcidin levels significantly higher than non-MetS counterpart. Since this was particularly evident in women with ferritin levels indicating true iron deficiency (i.e. <30 µg/l) where hepcidin is generally almost completely suppressed [12], this suggests that some MetS-related factors may affect hepcidin in this subgroup. On the other hand, the influence of MetS per se on hepcidin levels appears limited when iron stores are abundant. Recent experimental studies have found that leptin, one of the main adipokines, is able to stimulate hepatic hepcidin production [28], and a positive correlation has been found between serum levels of leptin and hepcidin in obese children [29]. Our results may warrant further studies on adults in this direction, particularly focusing on differences by gender. Indeed, the reason(s) why we observed an independent influence on hepcidin only in women remain to be elucidated. Nonetheless, some clues in literature also suggest that the link between iron and dysmetabolic features may be particularly relevant in women. Sheu et al. found a relationship between ferritin and insulin resistance only in women but not in men [15]. Similarly, the largest prospective study showing ferritin as an independent predictor of future development of type 2 diabetes mellitus included only women [16].

Chronic Hyperhepcidinemia in Metabolic Syndrome: more than Simply a Bystander?

Whatever the mechanism(s) behind, this study establishes for the first time at population level that hepcidin levels tend to be high in MetS. In view of the rapidly growing evidence for pleiotropic effects of hepcidin, this may have relevant implications for the MetS pathophysiology. First, studies in cellular models have recently demonstrated that hepcidin binding to ferroportin is able to activate Janus kinase 2/Signal Transducer and Activator 3 (Jak2/STAT3) signaling, leading in turn to an increased production of Suppressor of cytokine signaling 3 (SOCS3) [30], a central player in inducing hepatic steatosis, and MetS in mouse models [31]. Thus, hyperhepcidinemia might prime a vicious circle worsening MetS through SOCS3 induction over time. Second, high hepcidin levels may theoretically contribute to the well-known cardiovascular morbidity in MetS subjects. Indeed, three very recent experimental studies [32]–[34] have concordantly indicated that hepcidin may promote atherosclerosis, particularly by destabilizing the plaques through macrophage overactivation after erythrophagocytosis [34].

Study Limitations

Due to its observational design, our study cannot provide any mechanistic explanation, particularly with regards to whether increased hepcidin levels are cause or consequence of insulin resistance in subjects with MetS. Similarly, the lack of data on insulin levels precluded a direct analysis of the relationship between hepcidin and estimates of insulin resistance.

Conclusions

Our population study provides the first evidence for chronic hyperhepcidinemia as a new additional feature of MetS. The strong association between hepcidin and ferritin, as well as their parallel behavior as a function of increasing number of MetS features, suggest that hyperhepcidinemia may occur mainly in response to mild-to-moderate increase of body iron stores. Due to the recently discovered pleiotropic effects of hepcidin, our study suggests future investigations on the possible role of this hormone in worsening insulin resistance and in promoting the cardiovascular complications of MetS.

Supporting Information

Author Contributions

Conceived and designed the experiments: DG OO CC DT. Performed the experiments: NC MC AC MT GB SP. Analyzed the data: NM MT GP CM FB DM CS. Contributed reagents/materials/analysis tools: CM GP. Wrote the paper: DG NM.

References

  1. 1.Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356–359.
  2. 2.Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640–1645.
  3. 3.Moirand R, Mortaji AM, Loréal O, Paillard F, Brissot P, et al. (1997) A new syndrome of liver iron overload with normal transferrin saturation. Lancet 349: 95–97.
  4. 4.Riva A, Trombini P, Mariani R, Salvioni A, Coletti S, et al. (2008) Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J Gastroenterol 14: 4745–4752.
  5. 5.Dongiovanni P, Fracanzani AL, Fargion S, Valenti L (2011) Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 55: 920–932.
  6. 6.Adams PC, Barton JC (2011) A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol 55: 453–458.
  7. 7.Ganz T (2011) Hepcidin and iron regulation, 10 years later. Blood 117: 4425–4433.
  8. 8.Hentze MW, Muckenthaler MU, Galy B, Camaschella C (2010) Two to tango: regulation of Mammalian iron metabolism. Cell 142: 24–38.
  9. 9.Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090–2093.
  10. 10.Wrighting DM, Andrews NC (2006) Interleukin-6 induces hepcidin expression through STAT3. Blood 108: 3204–3209.
  1. 11.Castagna A, Campostrini N, Zaninotto F, Girelli D (2010) Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 73: 527–536.
  1. 12.Traglia M, Girelli D, Biino G, Campostrini N, Corbella M, et al. (2011) Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet 48: 629–634.
  1. 13.Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, et al. (2011) Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 117: e218–225.
  1. 14.Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, et al. (2005) Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 28: 2061–2063.
  1. 15.Sheu WH, Chen YT, Lee WJ, Wang CW, Lin LY (2003) A relationship between serum ferritin and the insulin resistance syndrome is present in non-diabetic women but not in non-diabetic men. Clin Endocrinol (Oxf) 58: 380–385.
  1. 16.Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, et al. (2004) Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 291: 711–717.
  1. 17.Jehn ML, Guallar E, Clark JM, Couper D, Duncan BB, et al. (2007) A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 165: 1047–1054.
  1. 18.Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, et al. (2009) The role of iron in type 2 diabetes in humans. Biochim Biophys Acta 1790: 671–681.
  1. 19.Yokomori N, Iwasa Y, Aida K, Inoue M, Tawata M, et al. (1991) Transcriptional regulation of ferritin messenger ribonucleic acid levels by insulin in cultured rat glioma cells. Endocrinology 128: 1474–1480.
  1. 20.Ackerman D, Gems D (2012) Insulin/IGF-1 and Hypoxia Signaling Act in Concert to Regulate Iron Homeostasis in Caenorhabditis elegans. PLoS Genet 8: e1002498.
  1. 21.Cook JD, Flowers CH, Skikne BS (2003) The quantitative assessment of body iron stores. Blood 101: 3359–3364.
  1. 22.Fernandez-Real JM, Lopez-Bermejo A, Ricart W (2002) Cross-talk between iron metabolism and diabetes. Diabetes 51: 2348–2354.
  1. 23.Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, et al. (2012) Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 55: 77–85.
  1. 24.Ruivard M, Lainé F, Ganz T, Olbina G, Westerman M, et al. (2009) Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol 50: 1219–1225.
  1. 25.Trombini P, Paolini V, Pelucchi S, Mariani R, Nemeth E, et al. (2011) Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome. Liver Int 31: 994–1000.
  1. 26.Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, et al. (2008) Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 87: 1374–1383.
  1. 27.Bekri S, Gual P, Anty R, Luciani N, Dahman M, et al. (2006) Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 131: 788–796.
  1. 28.Chung B, Matak P, McKie AT, Sharp P (2007) Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. Journal of Nutrition 137: 2366–2370.
  1. 29.del Giudice EM, Santoro N, Amato A, Brienza C, Calabrò P, et al. (2009) Hepcidin in obese children as a potential mediator of the association between obesity and iron deficiency. J Clin Endocrinol Metab 94: 5102–5107.
  1. 30.De Domenico I, Zhang TY, Koening CL, Branch RW, London N, et al. (2010) Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest 120: 2395–2405.
  1. 31.Ueki K, Kondo T, Tseng YH, Kahn CR (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A 101: 10422–10427.
  1. 32.Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, et al. (2011) Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol 31: 683–690.
  1. 33.Saeed O, Otsuka F, Polavarapu R, Karmali V, Weiss D, et al. (2012) Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol 32: 299–307.
  1. 34.Li JJ, Meng X, Si HP, Zhang C, Lv HX, et al. (2012) Hepcidin Destabilizes Atherosclerotic Plaque via Overactivating Macrophages After Erythrophagocytosis. Arterioscler Thromb Vasc Biol 32: 1158–1166.